Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cipla Vice Chair Explores Lung Leadership Vision With Biosimilars Opportunities

Samina Hamied Also Discusses Industry’s Expectations From Indian Government

Executive Summary

Executive vice chairperson of Cipla Samina Hamied talks to Generics Bulletin about the company’s intention to become global lung leaders on the back of biosimilars opportunities and its inhalation assets. As well as discussing Cipla’s three-year strategy, Hamied – who is also the vice president of IPA – discusses creating a favorable regulatory and policy landscape in India. 

You may also be interested in...



Cipla Remains Upbeat On Abraxane As US Generic Competition Looms

Cipla has provided the latest on its US complex pipeline ahead of several potential launches in the firm’s upcoming 2022/23 financial year. The Indian firm enjoyed 6% group revenue growth in Q3 FY2022 and is on track to hit its EBITDA margin target.

Cipla Builds On Albuterol Share As Investors Await FY23 US Revenue Delta

Cipla signals more US momentum with headroom for albuterol market share expansion, promising prospects for generic Brovana and strong launch line-up in FY23, but analysts also keep close eye on regulatory pre-approval inspection timelines.

ANI Delivers On Cortrophin Gel US Launch

ANI Pharmaceuticals has finally delivered its long-awaited launch of purified Cortrophin Gel (repository corticotropin injection) in the US, accompanying the launch with its ‘Cortrophin In Your Corner’ dedicated program to increase access and provide reimbursement support.

Topics

Related Companies

UsernamePublicRestriction

Register

GB151550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel